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ABSTRACT  
Objective: In the present study, a series of novel 1,3,4-oxadiazole derivatives (3a-3q) were designed, synthesized and evaluated for antioxidant and 
anti-inflammatory activities.  
Methods: The title compounds were designed and docked onto the COX-2 enzyme (3LN1) protein using SYBYLX 2.1. 2-substituted-5-(5-
nitrobenzofuran-2-yl)-1,3,4-oxadiazole derivatives (3a-3p) were synthesized from acid catalyzed dehydrative cyclization of 5-nitrobenzofuran-2-
carbohydrazide (2) with various heteroaryl/aryl/aliphatic carboxylic acid derivatives. And 5-(5-nitrobenzofuran-2-yl)-1,3,4-oxadiazole-2-thiol (3q) 
was synthesized on reacting the hydrazide derivative 2 with carbon disulfide. The synthesized compounds were evaluated for in vitro antioxidant 
property by DPPH radical scavenging assay method and in vivo anti-inflammatory activity by carrageenan induced paw edema method.  
Results: The synthesized 1,3,4-oxadiazole derivatives (3a-3q) were characterized on the basis of LCMS, 1HNMR [13]CNMR, IR and elemental 
analysis. The title compounds 3a-3q exhibited significant antioxidant efficacy ranging from 34 to 86%and the results of anti-inflammatory 
evaluation revealed that compounds 3c, 3e and 3d exhibited substantial anti-inflammatory activity of 72, 68 and 65%, respectively, at a dose of 50 
mg kg-1. 
Conclusion: A significant correlation was observed between the in silico study and the anti-inflammatory results. The anti-inflammatory results 
highlight the synthesized compounds 3c, 3e and 3d could be considered as possible hit as therapeutic agents.  
Keywords: Benzofuran, Oxadiazole, Antioxidant, Anti-inflammatory. 
 
INTRODUCTION 
Non steroidal anti-inflammatory drugs (NSAID’s) are the choice of 
drugs for the treatment/management of rheumatoid arthritis. 
Osteoarthritis and other pain conditions [1,2]. NSAID’s tops the lists 
of self medication and are also the frequently prescribed medication 
for all clinical conditions associated with pain and inflammation. 
NSAID’s act via suppression of prostaglandin biosynthesis by 
inhibiting the enzyme prostaglandin endoperoxidase, known as 
cyclooxygenase (COX), COX mediates the production of 
prostaglandins, prostacyclins and thromboxanes from arachidonic 
acid [3]. 
COX exists in two isotherms, COX-1 and COX-2, which are regulated 
and expressed differently [4-6]. COX-2 isoenzyme selectively 
mediates inflammatory signals and COX-1 isoenzyme regulates the 
mucus formation and thromboxan production, and provides 
cytoprotection in the gastrointestinal tract (GIT) [7,8]. Most of the 
currently available NSAIDs in clinical use like diclofenac, mefenamic 
acid, ibuprofen etc., are mainly non-selective COX inhibitors or 
exhibit greater selectivity for COX-1 than COX-2 [3]. Thus, with 
increased frequency and chronic use of these non-selective NSAID’s, 
secondary clinical condition like dyspepsia, gastroduodenal ulcers, 
gastritis bleeding and renal disorders are precipitated [9-11]. 
Whereas, COX-2 selective NSAIDs like celecoxib, rofecoxib, 
valdecoxib etc., are associated with serious cardiovascular problems 
due to the increased platelet aggregation [11,12]. 
Literature studies emphasize the importance of inhibition of 5-
lipoxygenase (5-LOX) enzyme, as the leucotrienes play an important 
role in blood coagulation and GIT irritation [13,14]. Thus, inhibition 
of 5-LOX will be helpful in attenuating the formation of gastric ulcer 
during long term therapy of non-selective and COX-1 selective 
NSAID’s [15], and, ameliorate the prothrombotic tendency resulting 
from COX-2 inhibition by the NSAID’s [16].  
Studies on 1,3,4-oxadiazoles highlight their importance in inhibiting 
5-LOX, thus reducing gastric ulcer formation, apart from suppressing 
prostaglandin anabolism from arachidonic acid by inhibiting the 
COX enzyme, thus highlighting its importance as anti-inflammatory 
agent and nonulcerogenic nature [3,17,18]. Hence, 1,3,4-oxadiazoles 
have been widely explored for its anti-inflammatory property [19-
30].1,3,4-oxadiazole derivatives are also reported for their broad 
spectrum of biological activitieslike anticonvulsant [31,32], 
antidepressant [33], anticancer [34,35], analgesic [36,37], 
antibacterial [38-41], antifungal [42,43], antimycobacterial 
[29,44,45], anthelmintic [25], hypoglycemic [46] and antiangiogenic 
[47] etc., indicating 1,3,4-oxadiazole is a physiologically active 
nucleus and an imperative scaffold on which therapeutic molecules 
are designed and developed. In view of these observations, 
seventeen novel 2-substituted-5-(5-nitrobenzofuran-2-yl)-1,3,4-
oxadiazole derivatives (3a-3p) were designed as potential COX-2 
inhibitors and predicted to have strong therapeutic benefit as anti-
inflammatory agents. The designed molecules were synthesized and 
evaluated for their anti-inflammatory activity. 
MATERIALS AND METHODS 
The chemicals used were purchased from Fluka Chemicals. Mumbai, 
India, and the solvents were purified by distillation if necessary and 
residual water was removed. Melting points were determined in 
open capillary tube and are uncorrected. TLC was used to assess the 
progress/completion of the reactions and the purity of the 
synthesized compounds using ethyl acetate and hexane (8:2) as 
solvent system and iodine vapors as visualizing agent. The IR spectra 
were recorded using Shimadzu FTIR-8400, Japan, by KBr disc pellet 
method and only noteworthy absorption levels (cm-1) are listed, 
1HNMR spectra were recorded using Brucker AC-400 MHz FT NMR 
spectrophotometer at 400 MHz with deuteriated dimethyl sulfoxide 
(DMSO-d6) as solvent and tetramethylsilane (TMS) as internal 
standard (chemical shifts in δ, ppm), [13]CNMR spectra were 
recorded using Bruker DSX 300 MHz FT NMR spectrophotometer at 
100 MHZ with deuteriated dimethyl sulfoxide (DMSO-d6) as solvent 
and mass spectra were recorded using JEOL GCMATE II GC-MS. 
Elementary analysis of final compounds were recorded using 
Thermo Finnigan FLASH EA 1112 CHNS analyser and all the 
compounds gave satisfactory elemental analysis. 
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Synthesis of ethyl 5-nitrobenzofuran-2-carboxylate(1) 
To the solution of 2-hydroxy-5-nitrobenzaldehyde (16.7 g, 0.10 mol) 
in dry acetone (50 mL), ethyl 2-chloroacetate (18.3 mL, 0.15 mol) 
and activated anhydrous potassium carbonate (12.0 g) were added 
and the mixture was heated to reflux with stirring for 6 h. The 
progress of the reaction was monitored by TLC. On completion of the 
reaction, the reaction mixture was cooled to room temperature and 
filtered. The filtrate was concentrated and poured in to the crushed 
ice to obtain the solid product 3. The product was recrystallized 
using rectified sprit as solvent. Yield: 72 %, mp 121-123 °C, Rf: 0.71, 
IR (KBr) 3030 (C=C), 1737 (C=O),1529 (N-O, NO2), 1432 (C-O-C); 
1HNMR (400 MHz, DMSO-d6,) δ 7.6-7.4 (m, 4H, benzofuran), 2.3 (d, J 
= 9.4 Hz, 2H, COOCH2), 1.8 (t, J = 12.6 Hz, 3H, COOCH2CH3). 
Synthesis of 5-nitrobenzofuran-2-carbohydrazide (2) 
To the solution of ester derivative 1 (23.5 g, 0.1 mol) in ethanol (30 
mL), hydrazine monohydrate (10.0 mL, 0.20 mol) was added and the 
mixture was heated to reflux for 8 h. The progress of the reaction 
was monitored by TLC. On completion of the reaction, the reaction 
mixture was cooled to room temperature and allowed to cool in the 
refrigerator overnight to precipitate the acid hydrazide2. Then the 
product was recrystallized using rectified sprit as solvent. Yield: 67 
%, mp154-155 °C, Rf: 0.74, IR (KBr) 3398-3450 (NH2, NH), 3045 
(C=C), 1718 (C=O), 1521 (N-O, NO2),1432 (C-O-C) cm-1; 1HNMR (400 
MHz, DMSO-d6,) δ 11.8 (s, 1H, CONH), 7.8-7.3 (m, 4H, ArH), 4.7 (s, 2H, 
NHNH2); [13]C NMR (100 MHz, DMSO-d6): δ 113.4 (C3), 121.3 (C7), 
124.9 (C4), 125.9 (C6), 132.4 (C9),146.3 (C2), 159.7 (C5), 163.6 (C8), 
174.8 (-CONH). 
General procedure for the synthesis of 2-substituted-5-(5-
nitrobenzofuran-2-yl)-1,3,4-oxadiazole derivatives (3a-3p) 
The acid hydrazide 2 was condensed with various 
heteroaryl/aryl/aliphatic carboxylic acids to afford the title 
oxadiazole derivatives.  
To the solution of acid hydrazide 2 (2.2 g, 0.01 mol) in ethanol (25.0 
mL), carboxylic acid derivatives (0.01 mol) and phosphorous 
oxychloride (1.6 mL, 0.01 mol) were added slowly in an exhaustion 
chamber and heated to reflux for 8 -12 h. The progress of the 
reaction was monitored by TLC. On completion of the reaction, the 
reaction mixture was cooled to room temperature and crushed ice 
was added to obtain oxadiazole derivative (3a-3q). The product was 
recrystallized using rectified sprit as solvent. 
2-(5-nitrobenzofuran-2-yl)-1,3,4-oxadiazole(3a): Yield: 82 %, 
mp162-163 °C, Rf: 0.75, IR(KBr) 3026 (C=C), 1592 (C=N), 1523 (N-O, 
NO2),1424 (C-O-C) cm-1; 1HNMR(400 MHz, DMSO-d6) δ 8.2 (s, 1H, CH, 
oxadizole),7.1-6.9 (m, 4H); [13]C NMR (100 MHz, DMSO-d6): δ 121.2 
(C3), 123.1 (C7), 124.5 (C4), 124.9 (C6), 131.7 (C9),147.8 (C2), 161.1 
(C5), 164.8 (C8), 169.3 (C5, oxadiazole), 171.9 (C2, oxadiazole). MS 
m/z(%):231.0291 (24) [M+]; Anal. Calcd for C10H5N3O4: C 51.96, H 
2.18, N 18.18,Found C 51.92, H 2.14, N 18.13. 
2-methyl-5-(5-nitrobenzofuran-2-yl)-1,3,4-oxadiazole(3b): 
Yield: 86 %, mp 167-168 °C, Rf: 0.65, IR (KBr) 3016 (C=C), 1613 
(C=N), 1526 (N-O, NO2), 1425 (C-O-C) cm-1; 1HNMR (400 MHz, 
DMSO-d6) δ 7.9-7.4 (m, 4H), 1.2 (s, 3H, CH3); [13]C NMR (100 MHz, 
DMSO-d6) δ26.7 (CH3),119.2 (C3), 121.1 (C7), 124.7 (C4), 126.3 (C6), 
129.7 (C9),148.8 (C2), 159.1 (C5), 161.4 (C8), 168.2 (C5, oxadiazole), 
171.4 (C2, oxadiazole).; MS m/z(%): 245 (35) [M+]; Anal. Calcd for 
C11H7N3O4: C 53.88, H 2.88, N 17.14, Found C 53.79, H 2.72, N 17.08. 
2-ethyl-5-(5-nitrobenzofuran-2-yl)-1,3,4-oxadiazole (3c): Yield: 
78 %, mp 181-183 °C, Rf: 0.69, IR (KBr) 3021 (C=C), 1643 (C=N), 
1542 (N-O, NO2), 1431 (C-O-C) cm-1; 1HNMR (400 MHz, DMSO-d6) δ 
7.7-7.3 (m, 4H), 1.4 (d, J = 11.7 Hz, 2H, CH2), 0.8 (t, J = 12.8 Hz, 3H, 
CH3); [13]C NMR (100 MHz, DMSO-d6) δ23.4 (CH3),34.2 (CH2), 114.7 
(C3), 118.3 (C7), 122.6 (C4), 124.3 (C6), 127.6 (C9),143.3 (C2), 157.6 
(C5), 159.2 (C8), 163.4 (C5, oxadiazole), 168.2 (C2, oxadiazole).;MS 
m/z(%): 259 (20) [M+]; Anal. Calcd for C12H9N3O4: C 55.60, H 3.50, N 
16.21, Found C 55.46, H 3.39, N 16.13 
5-(5-nitrobenzofuran-2-yl)-2-propyl-1,3,4-oxadiazole (3d): 
Yield: 76 %, mp 189-191 °C, Rf: 0.74, IR (KBr) 3019 (C=C), 1607 
(C=N), 1519(N-O, NO2), 1436 (C-O-C) cm-1; 1HNMR (400 MHz, DMSO-
d6) δ7.4-7.1 (m, 4H), 1.6 (d, J = 11.4 Hz, 4H, (CH2)2), 1.1 (t, J = 14.6 Hz, 
3H, CH3); [13]C NMR (100 MHz, DMSO-d6) δ19.8 (CH3),29.7 (2C, 
CH2), 119.2 (C3), 121.8 (C7), 123.3 (C4), 126.7 (C6), 131.1 (C9),147.2 
(C2), 157.1 (C5), 160.4 (C8), 165.6 (C5, oxadiazole), 169.4 (C2, 
oxadiazole); MS m/z(%): 273 (20) [M+]; Anal. Calcd for C13H11N3O4: C 
57.14, H 4.06, N 15.38, Found C 57.21, H 4.19, N 15.46. 
1-[5-(5-nitrobenzofuran-2-yl)-1,3,4-oxadiazol-2-yl]ethanol 
(3e): Yield: 68 %, mp 176-177 °C, Rf: 0.59, IR (KBr) 3353 (OH), 3024 
(C=C), 1589 (C=N), 1522 (N-O, NO2),1416 (C-O-C) cm-1; 1HNMR (400 
MHz, DMSO-d6) δ9.3 (s, 1H, OH), 7.8-7.4 (m, 4H), 2.1 (d, J = 19.2 Hz, 
1H, CH), 1.8 (t, J = 14.8 Hz, 3H, CH3); [13]C NMR (100 MHz, DMSO-d6) 
δ26.2 (CH3),34.1 (CH), 117.1 (C3), 119.3 (C7), 121.7 (C4), 127.1 (C6), 
132.4 (C9),148.8 (C2), 159.4 (C5), 163.1 (C8), 167.2 (C5, oxadiazole), 
171.1 (C2, oxadiazole); MS m/z(%): 275 (42) [M+]; Anal. Calcd for 
C12H9N3O5: C 52.37, H 3.30, N 15.27, Found C 52.46, H 3.39, N 15.42. 
[5-(5-nitrobenzofuran-2-yl)-1,3,4-oxadiazol-2-yl]methanamine 
(3f): Yield: 76 %, mp 213-214 °C, Rf: 0.62, IR (KBr) 3324 (NH2), 3249 
(NH), 3021 (C=C), 1612 (C=N), 1516 (N-O, NO2),1266 (C-O-C) cm-1; 
1HNMR (400 MHz, DMSO-d6) δ7.9-7.4 (m, 4H), 4.9 (s, 2H, CH2NH2), 
2.1 (d, J = 12.6 Hz, 2H, CH2); [13]C NMR (100 MHz, DMSO-d6) δ31.2 
(CH2), 119.2 (C3), 121.9 (C7), 124.3 (C4), 127.8 (C6), 131.9 (C9),146.1 
(C2), 161.1 (C5), 165.5 (C8), 169.7 (C5, oxadiazole), 173.6 (C2, 
oxadiazole);MS m/z(%): 360 (25) [M+]; Anal. Calcd for C11H8N4O4: C 
50.77, H 3.10, N 21.53, Found C 50.89, H 3.36, N 21.78. 
5-(5-nitrobenzofuran-2-yl)-2-phenyl-1,3,4-oxadiazole 
(3g):Yield: 69 %, mp 217-218 °C, Rf: 0.55, IR (KBr) 3027 (C=C), 1593 
(C=N), 1509 (N-O, NO2),1411 (C-O) 1278 (C-O-C) cm-1; 1HNMR (400 
MHz, DMSO-d6) δ 8.1-7.8 (m, 9H); [13]C NMR (100 MHz, DMSO-d6) 
δ117.2 (C3), 121.1 (C7), 123.5 (C4), 125.4 (C1 phenyl), 127.1 (2C, C2 
and C6 phenyl), 127.8 (C6), 129.2 (2C, C3 and C5 phenyl), 129.8 (C4 
phenyl), 134.2 (C9),148.4 (C2), 163.7 (C5), 166.4 (C8), 169.2 (C5 
oxadiazole), 172.1 (C2 oxadiazole); MS m/z (%): 307 (18) [M+]; Anal. 
Calcd for C16H9N3O4: C 62.54, H 2.95, N 13.68, Found C 62.78, H 3.11, 
N 13.82. 
5-(5-nitrobenzofuran-2-yl)-2-(2-nitrophenyl)-1,3,4-oxadiazole 
(3h):Yield: 58 %, mp 227-228 °C, Rf: 0.67, IR (KBr) 3021 (C=C), 1632 
(C=N), 1526, 1521(N-O, NO2),1425 (C-O), 1264 (C-O-C) cm-1; 1HNMR 
(400 MHz, DMSO-d6) δ8.1-7.9 (m, 8H); [13]C NMR (100 MHz, DMSO-
d6) δ120.9 (C3), 122.7 (C7), 126.1 (C1nitrophenyl),127.1 (C4), 128.8 
(C6), 131.4 (C4nitrophenyl), 133.9 (C5nitrophenyl),134.1 (C9), 135.7 
(C3nitrophenyl), 136.5 (C5nitrophenyl), 147.8 (C2), 159.3 
(C2nitrophenyl), 163.6 (C5), 168.2 (C8), 169.7 (C5, oxadiazole), 173.4 
(C2, oxadiazole); MS m/z(%): 352 (20) [M+]; Anal. Calcd for 
C16H8N4O6: C 54.55, H 2.29, N 15.91, Found C 54.64, H 2.35, N 16.16. 
2-(3,5-dinitrophenyl)-5-(5-nitrobenzofuran-2-yl)-1,3,4-
oxadiazole (3i):Yield: 61 %, mp 288-289 °C, Rf: 0.48, IR (KBr) 3029 
(C=C), 1622 (C=N), 1524, 1516 (N-O, NO2), 1424 (C-O), 1261 (C-O-C) 
cm-1; 1HNMR (400 MHz, DMSO-d6) δ8.2-7.9 (m, 7H); [13]C NMR (100 
MHz, DMSO-d6) δ123.2 (C3), 124.1 (C7), 126.7 (C4), 127.1 (C1 
phenyl),128.7 (C6), 133.9 (2C, C2 and C6dinitrophenyl), 134.4 (C9), 
148.1 (C2), 148.2 (C4dinitrophenyl), 158.7 (2C, C3 and 
C5dinitrophenyl), 166.1 (C5), 168.4 (C8), 169.9 (C5, oxadiazole), 173.2 
(C2, oxadiazole); MS m/z(%): 397 (34) [M+]; Anal. Calcd for 
C16H7N5O8: C 48.37, H 1.78, N 17.63, Found C 48.31, H 1.65, N 17.66. 
5-(5-nitrobenzofuran-2-yl)-2-(4-nitrophenyl)-1,3,4-oxadiazole 
(3j):Yield: 67 %, mp 234-235 °C, Rf: 0.60, IR (KBr) 3027 (C=C), 1611 
(C=N), 1522, 1517 (N-O, NO2),1409 (C-O) 1272 (C-O-C) cm-1; 1HNMR 
(400 MHz, DMSO-d6) δ 7.9-7.6 (m, 8H); [13]C NMR (100 MHz, DMSO-
d6) δ121.6 (C3), 123.8 (C7), 126.2 (C4), 126.8 (C1 phenyl), 128.2 (C6), 
129.8 (2C, C2 and C6nitrophenyl), 134.9 (C9),135.1 (2C, C3 and 
C5nitrophenyl), 148.1 (C2), 158.3 (C4nitrophenyl), 164.3 (C5), 167.9 
(C8), 169.6 (C5, oxadiazole), 171.8 (C2, oxadiazole); MS m/z(%): 352 
(26) [M+]; Anal. Calcd for C16H8N4O6: C 54.55, H 2.29, N 15.91, Found 
C 54.31, H 2.15, N 15.66. 
5-(5-nitrobenzofuran-2-yl)-2-styryl-1,3,4-oxadiazole (3k):Yield: 
58 %, mp 246-247 °C, Rf: 0.55, IR (KBr) 3026 (C=C), 1593 (C=N), 
1523 (N-O, NO2), 1416 (C-O) 1271 (C-O-C) cm-1; 1HNMR (400 MHz, 
DMSO-d6) δ7.8 (d, J = 14.6Hz, 1H, CH=CHC6H5), 7.7-7.2 (m, 9H), 6.3 
(d, J = 14.2Hz, 1H, CHC6H5); [13]C NMR (100 MHz, DMSO-d6) δ119.2 
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(CH=CHC6H5), 121.6 (C3), 122.6 (C7), 124.9 (C4), 127.4 (2C, C2 and C6 
phenyl), 127.8 (C6), 128.3 (2C, C3 and C5 phenyl), 129.4 (C4 phenyl), 
134.2 (C1 phenyl),136.1 (C9), 147.4 (C2),148.1 (CH=CHC6H5), 165.2 
(C5), 169.1 (C8), 171.7 (C5 oxadiazole), 173.6 (C2 oxadiazole); MS m/z 
(%): 333 (18) [M+]; Anal. Calcd for C18H11N3O4: C 64.86, H 3.33, N 
12.61, Found C 64.97, H 3.41, N 12.87. 
2-(2-aminophenyl)-5-(5-nitrobenzofuran-2-yl)-1,3,4-oxadiazole 
(3l):Yield: 60 %, mp 257-258 °C, Rf: 0.69, IR (KBr) 3318 (NH2), 3251 
(NH), 3024 (C=C), 1631 (C=N), 1526 (N-O, NO2), 1422 (C-O), 1267 
(C-O-C) cm-1; 1HNMR (400 MHz, DMSO-d6) δ 8.1-7.9 (m, 8H), 5.6 (s, 
2H, NH2); [13]C NMR (100 MHz, DMSO-d6) δ121.6 (C3), 123.4 (C7), 
125.2 (C1aminophenyl), 126.7 (C4), 129.3 (C6), 133.7 
(C4aminophenyl), 134.6 (C5aminophenyl), 135.2 (C9), 136.7 
(C3aminophenyl), 138.1 (C5aminophenyl), 149.8 (C2), 161.1 
(C2aminophenyl), 167.8 (C5), 169.3 (C8), 171.4 (C5 oxadiazole), 176.1 
(C2 oxadiazole); MS m/z(%): 322 (15) [M+]; Anal. Calcd for 
C16H10N4O4: C 59.63, H 3.13, N 17.38, Found C 59.64, H 3.15, N 17.42. 
2-(4-aminophenyl)-5-(5-nitrobenzofuran-2-yl)-1,3,4-oxadiazole 
(3m):Yield: 68 %, mp 234-236 °C, Rf: 0.74, IR (KBr) 3309 (NH2), 
3247 (NH), 3019 (C=C), 1629 (C=N), 1518 (N-O, NO2), 1434 (C-O-C) 
cm-1;1HNMR (400 MHz, DMSO-d6) δ 7.9-7.7 (m, 8H), 5.4 (s, 2H, NH2); 
[13]C NMR (100 MHz, DMSO-d6) δ119.8 (C3), 122.2 (C7), 124.7 (C4), 
126.2 (C1aminophenyl), 127.8 (C6), 129.3 (2C, C2 and 
C6aminophenyl), 132.6 (C9),134.3 (2C, C3 and C5aminophenyl), 147.3 
(C2), 156.1 (C4aminophenyl), 159.8 (C5), 162.3 (C8), 167.8 (C5, 
oxadiazole), 168.4 (C2, oxadiazole); MS m/z(%): 322 (25) [M+]; Anal. 
Calcd for C16H8N4O6: C 59.63, H 3.13, N 17.38 Found C 59.78, H 3.25, 
N 17.66. 
2-(2-hydroxyphenyl)-5-(5-nitrobenzofuran-2-yl)-1,3,4-
oxadiazole(3n):Yield: 52 %, mp 241-242 °C, Rf: 0.68, IR (KBr) 3326 
(OH), 3017 (C=C), 1617 (C=N), 1525 (N-O, NO2), 1272 (C-O-C) cm-1; 
1HNMR (400 MHz, DMSO-d6) δ10.7 (s, 1H, OH), 8.1-7.6 (m, 8H); 
[13]C NMR (100 MHz, DMSO-d6) δ118.2 (C3), 121.7 (C7), 124.8 
(C1hydroxyphenyl), 127.1 (C4), 129.6 (C6), 134.2 (C4hydroxyphenyl), 
135.1 (C5hydroxyphenyl), 136.4 (C9), 138.4 (C3hydroxyphenyl), 
142.7 (C5hydroxyphenyl), 147.4 (C2), 163.1 (C2hydroxyphenyl), 
169.2 (C5), 170.3 (C8), 173.7 (C5 oxadiazole), 176.9 (C2 oxadiazole); 
MS m/z(%): 323 (32) [M+]; Anal. Calcd for C16H9N3O5: C 59.45, H 
2.81, N 13.00, Found C 59.58, H 3.06, N 13.21. 
2-(4-hydroxyphenyl)-5-(5-nitrobenzofuran-2-yl)-1,3,4-
oxadiazole (3o):Yield: 56 %, mp 218-219 °C, Rf: 0.72, IR (KBr) 3335 
(OH), 3023 (C=C), 1597 (C=N), 1514 (N-O, NO2), 1478 (C-O-C) cm-1; 
1HNMR (400 MHz, DMSO-d6) δ10.1 (s, 1H, OH), 7.9-7.6 (m, 8H);[13]C 
NMR (100 MHz, DMSO-d6) δδ116.4 (C3), 120.6 (C7), 121.6 (C4), 127.1 
(C1hydroxyphenyl), 128.2 (C6), 129.8 (2C, C2 and C6hydroxyphenyl), 
133.7 (C9),136.2 (2C, C3 and C5hydroxyphenyl), 149.1 (C2), 157.8 
(C4hydroxyphenyl), 159.3 (C5), 163.5 (C8), 167.2 (C5, oxadiazole), 
169.3 (C2, oxadiazole); MS m/z(%): 323 (25) [M+]; Anal. Calcd for 
C16H9N3O5: C 59.45, H 2.81, N 13.00, Found C 59.72, H 2.97, N 13.16. 
5-(5-nitrobenzofuran-2-yl)-2-(pyridin-3-yl)-1,3,4-oxadiazole 
(3p):Yield: 69 %, mp 267-269 °C, Rf: 0.74, IR (KBr) 3025 (C=C), 
1621, 1624 (C=N), 1524 (N-O, NO2), 1455 (C-O-C) cm-1; 1HNMR (400 
MHz, DMSO-d6) δ 8.3-7.7 (m, 8H); [13]C NMR (100 MHz, DMSO-d6) 
δ120.5 (C3), 121.7 (C7), 124.6 (C4), 126.2 (C5pyridin-3-yl), 127.8 (C6), 
132.6 (C3pyridin-3-yl), 134.2 (C9), 137.1 (C4pyridin-3-yl), 148.4 (C2), 
159.1 (C6 pyridin-3-yl), 163.4 (C5), 165.9 (C8), 167.9 (C2 pyridin-3-yl), 
169.4 (C5 oxadiazole), 172.1 (C2 oxadiazole);MS m/z(%): 308(38) 
[M+]; Anal. Calcd for C15H8N4O4: C 58.45, H 2.62, N 18.18, Found C 
58.72, H 2.86, N 18.31. 
Synthesis of 5-(5-nitrobenzofuran-2-yl)-1,3,4-oxadiazole-2-
thiol (3q) 
To a solution of the acid hydrazide 2 (2.2 g, 0.01 mol) in ethanol 
(30.0 mL), equimolar quantities of carbon disulphide (3.8 mL, 0.05 
mol) and potassium hydroxide (2.8 g, 0.05 mol) were added. The 
contents were heated to reflux for 4 h. Distilled water was added 
followed by neutralization with dilute HCl, to obtain a solid mass 
product 3q. The product separated out, was filtered and 
recrystallized using methanol as solvent. Yield: 58 %, mp 283-284 
°C, Rf: 0.53, IR (KBr) 3087 (C=C), 2587 (SH), 1620 (C=N), 1527 (N-O, 
NO2),1283 (C-O-C) cm-1; 1HNMR (400 MHz, DMSO-d6) δ 12.9 (s, 1H, 
SH), 8.1-7.6 (m, 4H); [13]C NMR (400 MHz, DMSO-d6) δ 119.6 (C3), 
122.4 (C7), 123.8 (C4), 126.1 (C6), 133.2 (C9),147.2 (C2), 162.7 (C5), 
163.4 (C8), 168.9 (C5, oxadiazole), 173.3 (C2, oxadiazole); MS 
m/z(%): 263 (45) [M+]; Anal. Calcd for C10H5N3O4S: C 45.63, H 1.91, N 
15.96, S 12.18, Found C 45.69, H 2.07, N 16.11, S 12.39. 
In vitro antioxidant activity 
The in vitro antioxidant activity was carried out by DPPH radical 
scavenging assay method with suitable modification [51]. In brief, 
the assay was carried out using UV spectrophotometer at 517 nm. To 
the 1 mL solution of synthesized compounds (10-4 M), 1 mL DPPH 
solution (25 µM) was added into the test tube. The solution was 
incubated at 37 °C for 30 min and the absorbance of each solution 
was measured at 517 nm against the reagent blank solution. The 
ascorbic acid (25 µM) was used as the reference antioxidant. The 
experimental values summarized for DPPH radical scavenging 
assays are expressed as the mean ± standard error of mean (SEM). 
The percent free radical scavenging activity was calculated by the 
formula given below. 
%	Scavenging = Control	absorbance	–Test	absorbance
Control	absorbance 	× 100 
Pharmacology 
All the animal experimental procedures and protocols adapted in the 
study were reviewed and approved by the Institutional Animal 
Ethics Committee. The experimental procedures and protocols were 
in accordance with the guidelines of the CPCSEA, Ministry of Forests 
and Environment, Govt. of India. The animals were obtained from 
the JSS Medical college, Mysore, India, and were maintained in 
colony cages at 25 ± 2°C, relative humidity of 45-55%, under a 12 h 
light and dark cycle; they were fed standard animal feed. All the 
animals were acclimatized for a week before use. Animals were 
deprived of food 12 h prior to experiment and only water was 
allowed ad libitum. 
Anti-inflammatory evaluation  
Anti-inflammatory activity was evaluated by carrageenan-induced 
paw edema test using groups of albino rats weighing 100-120 g 
each, 6 rats per group, as per the reported method [19]. The first 
group was injected with 0.1 mL of carrageenan (1% solution in 
normal saline) in the plantar tissue of the right hind paw and served 
as untreated control. The positive control group was given 10 mg kg-
1 indomethacin one hour before carrageenan injection. The test 
compounds (3a–3q) were suspended in 0.5% carboxy methyl 
cellulose (CMC) and given to the rats orally at a dose of 50 mg kg-1 
one hours prior to carrageenan injection.  
Four hours after carrageenan administration, the paw volumes (mL) 
were measured using the mercury displacement technique with the 
help of a plethysmograph. The percent inhibition of paw edema was 
calculated by using the following formula. 
%	Inhibition = a− x
b− y × 100 
Where x is the mean paw volume of rats before the administration of 
carrageenan and/or test compounds or reference compound (test 
group), a is the mean paw volume of rats after the administration of 
carrageenan in the test group (drug/compound treated), b is the 
mean paw volume of rats after the administration of carrageenan in 
the control group and y is the mean paw volume of rats before the 
administration of carrageenan in the control group.  
The mean percent inhibition of indomethacin and tested compounds 
at 10 mg kg-1 concentrations were compared with control using 
repeated measures ANOVA with Dunnet’s test. The data obtained is 
expressed as mean ± standard error of mean (SEM).  
Molecular docking studies 
Crystallographicdata of the mouse COX-2 enzyme (PDB-ID: 3LN1) 
was used for docking studies, since the data on murine COX-2 have 
been reported in many studies [16]. The x-ray crystal structure of 
3LN1 was downloaded from (http: //www. pdb. org). 
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The protein structure of 3LN1 is well established with a 
hydrophobic active site and was determined at 2.4 Å resolution. The 
protein was prepared using a protein preparation module in SYBYLX 
2.1, where bond orders were assigned. Water and other residues 
were removed and the protein model was charged with AMBER7 
FF99. Ligands, 1,3,4-oxadiazoles 3a-3q were drawn in ChemDraw 
and molecules were converted into *. sdf using Open Babel software.  
Using the ligand preparation utility of SYBYLX 2.1, 3D structures 
were generated from 2D and the ligands were energy minimized 
using minimize module of SYBYL X 2.1 by applying molecular 
mechanics force fields (MMFF94s) and charged using Gasteiger- 
Marsili method. 
Molecular docking simulations were performed in order to 
distinguish the basic receptor-ligand interactions. The docking 
experiments were carried using the SYBYL X 2.1. The bound 
conformation of celecoxib was used as controls in order to define the 
active site in COX-2, and the optimized 3D-structuresof oxadiazole 
series 3a-3q was docked within 10 Å radius to find the most optimal 
binding pose of each ligand. The docking algorithm performs a series 
of hierarchical searches for locations of possible ligand affinity 
within the binding site of the enzyme. The docked molecules are 
ranked with total scores, highlighting the affinity to the enzyme core. 
This total score is a model energy function that combines empirical 
and force field based terms. 
RESULTS AND DISCUSSION 
Chemistry 
Synthesis of intermediate and target compounds was accomplished 
according to the steps depicted in scheme 1. The starting material ethyl 
5-nitrobenzofuran-2-carboxylate (1) was synthesized by condensing 
2-hydroxy-5-nitrobenzaldehyde with ethyl 2-chloroacetate in the 
presence of anhydrous potassium carbonate, and a catalytic amount of 
potassium iodide, with modification of the reported method [48]. The 
1HNMR spectra of compound 1, accounts for nine protons, of which 
four protons are of benzofuran moiety, which have resonated as 
multiplet between 7.46 and 7.61 ppm. A doublet at 1.81 ppm was 
attributed to the methyl protons of the ester, and the methylene 
protons of ester have resonated as a triplet at 2.34 ppm. The 
conversion of the ester to hydrazide function was carried out as per 
the reported method [49]. The ester derivative 1 was treated with 
excess of hydrazine monohydrate in absolute ethanol to undergo 
nucleophilic addition to yield the acid hydrazide derivative, 5-
nitrobenzofuran-2-carbohydrazide (2). In the [13]CNMR of the acid 
hydrazide derivative 2, the chemical signal at 174.8 ppm was 
attributed to the –CONH function of the hydrazide. In the 1HNMR of the 
acid hydrazide derivative 2, two isolated singlet at 11.82 and 4.79 ppm 
were attributed to the NH and NH2 protons of the hydrazide function, 
respectively and the mutiplet between 7.36 to 7.82 ppm was assigned 
to the four protons of the benzofuran moiety. 
A total of seventeen 1,3,4-oxadiazole derivatives 3a-3q were 
synthesized, the acid hydrazide derivative 2 was condensed with 
various hetroaryl/aryl/aliphatic carboxylic acids in presence of 
phosphorous oxychloride to undergo dehydrative cyclization as per 
the reported method [50]. On the other hand, the mercapto 
derivative 3q was prepared by treating the acid hydrazide 2 with 
carbon disulphide in the presence of potassium hydroxide as per the 
reported method [30].  
The 1HNMR spectra of compound 3a accounts for five protons, a 
mutiplet between 6.92 to 7.11 ppm can be attributed to the protons 
of the benzofuran moiety. A singlet 8.21 ppm can be attributed to the 
proton at C2 of the oxadiazole moiety. In the [13]CNMR spectra of 
compound 3b, the chemical signal at 26.71 ppm can be attributed to 
the methyl substitution at C2 position of the oxadiazole moiety and 
the same methyl group protons have resonated as an isolated singlet 
at 1.21 ppm in the 1HNMR spectra. The proton NMR spectra of 
compound 3c, with doublet at 1.43 ppm and a triplet at 0.86 ppm 
can be attributed for the methylene and the methyl protons of the 
ethyl group substitution at C2 position of the oxadiazole moiety, 
respectively. The rest of the compounds synthesized were also 
characterized similarly and data were found in agreement with the 
proposed structures. 
In vitro antioxidant evaluation  
The newly synthesized 1,3,4-oxadiazole derivatives (3a-3q) were 
evaluated for their free radical scavenging activity by 2,2-diphenyl-
1-picryl hydrazyl (DPPH) radical assay method using ascorbic acid 
as standard. The compounds 3a-3q exhibited significant scavenging 
activity ranging from 34 to 86% and the data are expressed in Mean 
± SEM in Table 1. 
 
Table 1: In vitro antioxidant activity of the test compounds 
S. 
No. 
Compound *Percentage free radical scavenging 
activity 
1. 3a 68.64 ± 2.17 
2. 3b 61.42 ± 1.76 
3. 3c 56.11 ± 1.47 
4. 3d 61.31 ± 2.04 
5. 3e 72.61 ± 1.34 
6. 3f 64.93 ± 1.85 
7. 3g 34.86 ± 2.12 
8. 3h 46.67 ± 2.31 
9. 3i 36.21 ± 1.81 
10. 3j 43.16 ± 2.07 
11. 3k 39.33 ± 1.57 
12. 3l 79.42 ± 3.09 
13. 3m 74.87 ± 2.54 
14. 3n 86.13 ± 1.84 
15. 3o 81.42 ± 3.12 
16. 3p 82.42 ± 1.34 
17. 3q 41.67 ± 1.27 
18. Ascorbic 
Acid  
89.17 ± 1.86 
*Results are expressed as the mean values from three independent 
experiments ± SEM. 
 
In vivo anti-inflammatory evaluation 
The title compounds, with significant antioxidant property were 
evaluated for in vivo anti-inflammatory activity at a dose of 50 
mg kg-1 by carrageenan induced paw edema method. 
Indomethacin at 10 mg kg-1 was used as reference standard and 
CMC as control. The result of the anti-inflammatory screening at 
the end of four hours after the administration of carrageenan 
highlighted compounds 3a-3q with edema reduction ranging 
from 9.1 to 72.5%, in comparison to 48.7% edema reduction 
seen with standard indomethacin. 
The result of anti-inflammatory evaluation highlighted that 
compound 3c (ethyl), 3e (ethan-1-ol), 3d (propyl) and 3f 
(methanamine)exhibited superior anti-inflammatory activity than 
that of indomethacin (48.7%) with an edema reduction of 72.5, 68.4, 
65.2 and 58.9%, respectively in comparison to the other set of 
oxadiazole derivatives (3a, 3b, 3g-3q). 
Interestingly, derivatives with aryl substitutionat position C2 of the 
oxadiazole series (3g-3p), compounds with electron donating 
substituents on the phenyl moiety; namely 3l (2-aminophenyl), 3m 
(4-aminophenyl), 3n (2-hydroxyphenyl) and 3f (4-hydroxyphenyl) 
exhibited substantial activity ranging from 32.7 to 44.9% edema 
reduction. On the other hand, compound 3p with pyridin-3-yl 
substitution proved to be the major exception of all the tested 
compounds with edema reduction of only 9.1%. Whereas, 
compounds 3b(methyl) and 3q (thiol) exhibited edema reduction of 
only 21.4 and 26.7%, respectively.  
The results of antioxidant and anti-inflammatory studies reveal 
correspondence between free radical scavenging efficacy and 
inhibition of induction of edema (percentage protection). The 
statistical analysis of the anti-inflammatory data obtained by 
Dunnet’s test revealed that the tested compounds exhibited 
significant (P< 0.001) anti-inflammatory activity compared to 
control. The percentage inhibition of inflammation by the test 
compounds at dose of 50 mg kg-1 at the end of four hours time 
intervals are expressed in mean ± SEM in Table 2. 
 
Table 2: In vivo anti-inflammatory activity of the test 
compounds at 50 mg kg-1 by carrageenan induced paw edema 




19. 3a 17.25 ± 0.72***
20. 3b 24.41 ± 1.14***
21. 3c 72.51 ± 1.16***
22. 3d 65.19 ± 2.07***
23. 3e 68.43 ± 2.16***
24. 3f 58.92 ± 2.10***
25. 3g 24.46 ± 1.15***
26. 3h 16.85 ± 1.24***
27. 3i 18.21 ± 2.19***
28. 3j 12.05 ± 0.82***
29. 3k 25.68 ± 1.38***
30. 3l 42.08 ± 1.36***
31. 3m 44.9 ± 0.66
32. 3n 38.85 ± 1.24***
33. 3o 32.71 ± 2.19***
34. 3p 09.14 ± 0.73***
35. 3q 26.68 ± 1.38***
36. Indomethacin (10 mg kg-1) 48.72 ± 1.61***
a Results are expressed as the mean values from
experiments ± SEM. 
b Data was analyzed by Dunnet’s test. n = 3; (***) equals 
 
Docking Studies 
The molecular modeling technique was used to explore
understand the protein/enzyme interactions with our designed 
1,3,4-oxadiazole library; and also to visualize the probable binding. 
The docking study was performed using theSYBYL X 2.
all the seventeen 2,5-disubstituted 1,3,4-oxadizoles were docked 
into the active site of the enzyme COX-2 (PDB:
structure of the enzyme along with its co crystallized ligand 
celecoxib, was downloaded from the RCSB protein data bank (
//www. pdb. org). The binding site of 3LN1, a typical cylindrical core 
of 23 Å between Ser516A, Ser339B and Asp510A concentrating the 
hydrophobic interaction. The ligand, celecoxib exhibited a docking 
score of 9.6292, with the main hydrophobic interactions with the 
surrounding residues His75A, Leu345A and Leu517A, strongly 
contributed to the stabilization with 3LN1. And 
and Val335A residues are involved in Vanderwall’s interaction with 
the akyl/haloakyl chain present in the celecoxib. The hydrogen 
bonding interaction of the amino group protons of the celecoxib 
were with the residues Gln178OE1 and His75. N
2.392 and 2.249 Å, respectively. The sulfonyl oxygen of the ligand 
celecoxib was involved in hydrogen bonding interaction with 
Arg499. HH11 and Phe504H residues at a distance of 2.114 and 
2.295 Å, respectively (Figure 1).  
The docking study revealed that the 1,3,4-oxadiazole derivatives 3a
3q, possessed high affinity towards 3LN1 (Figure 2
series, compound 3d (2-propyl derivative) generate
score (7.1399), the nitro group substitution at position C5 of the 
benzofuran moiety was involved showed hydrogen bond interaction 
with Arg499HH11 and Phe504H at a distance of 2.173 and 2.211 Å, 
respectively. The compound 3d was well aligned in the hydrophobic 
core of the 3LN1 (Figure 3). 
Compound 3e, 3c and 3f exhibited a docking score of 6.6198, 6.3832 
and 6.0524, respectively. Wherein, the nitro function at C
benzofuran moiety is involved in the hydrogen bond interaction 
with Arg499HH11 and Phe504H residues. Apart from the nitro 
group interaction, the compound 3c and 3f also exhibited hydrogen 
bond interaction between the nitrogen of the oxadiazole
AArg106HH12 residue.  
Compound 3k (2-styryl), 3h (2-nitro phenyl), 3g (phenyl), 3o (4
hydroxy phenyl), 3m (2-amino phenyl) and 3j (4
exhibited crash score of -4.7634, -4.7654, -4.9915, 
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and -8.0054 kcal mol-1, respectively. 
indicates inappropriate penetration of the ligand into the binding 
site of COX-2; 3LN1 resulting in the decreased forces of interaction 
with the amino acid. The results of docking studies and anti
inflammatory results reveal the
importance of docking studies and anti
Fig. 1: Graphical representation of the ligan
conformation onto 3LN1
Fig. 2: Energy minimized and conformationally analyzed 
structures alignedagainst 
protomol
Fig. 3: Docking of 5-(5-nitrobenzofuran
oxadiazole (3d) into the active site of 3LN1(yellow dotted line 
represents the hydrogen bonding interaction).
CONCLUSION 
A series of novel benzofuran encompassing 
designed with the help of molecular modelling and docking studies. 
The designed library of oxadiazoles
and evaluated for in vitro antioxidant property and 
inflammatory activity. The results of free radical scavenging activity 
by DPPH radicalassay method highlighted that the tested 
compounds 3a-3q exhibited significant scavenging activity. 
vivo anti-inflammatory activity was evaluated by carrageenan 
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induced paw edema method at dose of 50 mg kg-1. The anti-
inflammatory results highlight the synthesized compounds 3c, 3e 
and 3d could be considered as possible hit as therapeutic agents. It 
can be concluded that these compounds 3c, 3e and 3d certainly 
holds great promise towards good active leads in medicinal 
chemistry.  
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